Medicines (MDCO) Posts Q3 Loss of $0.06
More News related to MDCO
- Medicines Co. (MDCO) Releases Phase III Data for CHAMPION Program of Cangrelor
- The Medicines Company's Full Analysis of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patient Outcomes Following PCI
- Cleviprex Results Reported From Study in Patients With Intracerebral Hemorrhage
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Medicines (MDCO) Posts Q3 Loss of $0.06
More News related to Earnings
- Quicksilver Resources (KWK) Granted Motion for Partial Summary by Texas in BreitBurn (BBEP) Lawsuit
- American International Group (AIG) Implementing Benmosche's Compensation Agreement
- Sun American (SAMB) Receives Listing Rule 5450 Notification from NASDAQ
- Solutia (SOA) To Discontinue Manufacturing at its Plant in Cologne, Germany
- General Dynamics (GD) Business Unit Awarded $2.2B U.S. Army SAC Contract for 724 LAV's
The Medicines Company (NASDAQ: MDCO) reports Q3 EPS of $0.06, versus the analyst estimate of ($0.05). Revenue for the quarter was $98.80 million, which compares to the estimate of $96.99 million.
Related Categories
EarningsStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
